EUVIMEDEUVIMED entdecken
Querschnittstudie

Pharmaceutical company payments to medical school deans and university hospital directors in Japan: a nationwide cross-sectional study

Keita Shimizu, Akemi Hara, Piotr Ozieranski, Ivan D Florez iD, Yangqin Xun, Janne Estill, Yaolong Chen, Yudai Kaneda iD, Tetsuya Tanimoto, Akihiko Ozaki iD

International Journal for Quality in Health Care · 05.10.2026 · 38 (4)

DOI: 10.1093/intqhc/mzag170 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift International Journal for Quality in Health Care, online erschienen am 19.10.2026. Verfasst von Keita Shimizu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Governance Research Institute, Tokyo, Japan. Hauptthemen laut MEDLINE: Drug Industry, Conflict of Interest, Schools, Medical, Hospitals, University. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Medical Governance Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Financial relationships between pharmaceutical companies and the leaders of academic medical institutions may generate institutional conflicts of interest, yet payments to medical school deans and university hospital directors have not been examined nationally. We assessed the magnitude, concentration, and specialty pattern of pharmaceutical company payments to the leaders of all Japanese academic medical centres.

Methods

In this nationwide cross-sectional study, we identified the deans and main-hospital directors in post at all 82 universities with a medical school in Japan as of early 2026 (82 deans and 84 directors). Using payment disclosures from companies affiliated with the Japan Pharmaceutical Manufacturers Association, we aggregated personal payments (lecture, manuscript, and consulting fees) to each leader during fiscal year 2023 and described their amount, concentration, and distribution by specialty and payment category.

Results

Overall, 67 of 82 deans (81.7%) and 77 of 84 hospital directors (91.7%) received payments. Total payments were US$901 128 for deans (median US$4894) and US$1 843 565 for directors (median US$14 031). Payments were highly concentrated: the top decile of recipients accounted for 43.9% (deans) and 36.4% (directors) of the total, and lecture fees comprised 85.2% and 88.5% of payments, respectively. The highest-paid specialties were orthopaedic surgery, urology, and pharmacology among deans, and respiratory medicine, urology, and haematology among directors.

Conclusion

Pharmaceutical payments to the leaders of Japanese academic medical centres were common, substantial, and concentrated among a small number of individuals and specialties, supporting the case for prohibiting personal promotional payments to institutional leaders while they hold office, with public disclosure as a minimum floor rather than an endpoint.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug IndustryConflict of InterestSchools, MedicalHospitals, UniversityFaculty, MedicalJapanCross-Sectional StudiesHumansDisclosureAcademic Medical Centers

Stichwörter der Autor:innen

Japanacademic medical centresconflict of interestfinancial disclosureinstitutional conflict of interestpharmaceutical industry

Autor:innen und Institutionen

  • Medical Governance Research Institute, Tokyo, Japan.
  • Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
  • Clinical Research Center, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan.
  • Department of Social & Policy Sciences, University of Bath, Bath, United Kingdom.
  • Department of Pediatrics, University of Antioquia, Medellín, Colombia.
  • St Michael's Hospital, Unity Health Toronto, Toronto, Canada.

ORCID-Profile: Ivan D Florez, Yudai Kaneda, Akihiko Ozaki

Förderung

  • Medical Governance Research Institute

Zitieren

APA

Shimizu, K., Hara, A., Ozieranski, P., Florez, I. D., Xun, Y., Estill, J., Chen, Y., Kaneda, Y., Tanimoto, T., & Ozaki, A. (2026). Pharmaceutical company payments to medical school deans and university hospital directors in Japan: a nationwide cross-sectional study. International Journal for Quality in Health Care, 38(4). https://doi.org/10.1093/intqhc/mzag170

Vancouver

Shimizu K, Hara A, Ozieranski P, Florez ID, Xun Y, Estill J, et al. Pharmaceutical company payments to medical school deans and university hospital directors in Japan: a nationwide cross-sectional study. International Journal for Quality in Health Care. 2026;38(4). doi:10.1093/intqhc/mzag170

BibTeX
@article{Shimizu2026,
  author = {Shimizu, Keita and Hara, Akemi and Ozieranski, Piotr and Florez, Ivan D and Xun, Yangqin and Estill, Janne and Chen, Yaolong and Kaneda, Yudai and Tanimoto, Tetsuya and Ozaki, Akihiko},
  title = {Pharmaceutical company payments to medical school deans and university hospital directors in Japan: a nationwide cross-sectional study},
  journal = {International Journal for Quality in Health Care},
  year = {2026},
  volume = {38},
  number = {4},
  doi = {10.1093/intqhc/mzag170}
}
Kostenlos starten →